Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExPEC4V Safety and Immunogenicity in Healthy Adults
NCT03500679Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Primary completion
- Nov 2018
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ExPEC4V in invasive extraintestinal pathogenic Escherichia coli disease (IED), urinary tract infection (UTI), sponsored by Janssen Pharmaceutical. Started May 2018; status: completed.
02
Drugs
ExPEC4V
03
Conditions
invasive extraintestinal pathogenic Escherichia coli disease (IED)urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT03500679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03500679.